Quantum Leap Healthcare Collaborative

Quantum Leap Healthcare Collaborative is a U.S.-based nonprofit clinical research organization focused on accelerating patient-centered oncology development through adaptive platform trials and trial-enabling data infrastructure. The organization is best known for sponsoring and operating the I-SPY family of breast cancer trials, including I-SPY 2.2, and for launching the Phase 2 RECAST DCIS platform study in ductal carcinoma in situ. Beyond trial operations, QLHC also runs patient trial-matching services such as BreastCancerTrials.org and CTMatch and offers secure data-analysis capabilities through OneSource AI. Its model centers on integrating clinical care, biomarkers, imaging, and analytics to speed evaluation of multiple investigational therapies and treatment strategies in parallel. QLHC collaborates with academic investigators, pharmaceutical companies, diagnostics partners, and patient advocates rather than functioning as a traditional drug-discovery biotech with a proprietary wholly owned therapeutic pipeline.